Loading...
You have changed your country from
to
. Please be aware that this will change the currency in the purchasing process.
Products:Cardiovascular >> Angiogenesis >> Adhesion / ECM >> Matrix Metalloproteinases >> MMP
Overview
Product name
Anti-MMP13 antibody - Propeptide domain
See all MMP13 products (18) ...
Description
Rabbit polyclonal to MMP13 - Propeptide domain
Specificity
This antibody recognizes the Propeptide region of MMP13. The Propeptide region is shed during enzymatic activation of MMP13, and the antibody does not recognize the activated forms. The antibody can thus be used to discriminate between the zymogen and activated MMP13.
Tested applications
Cross reactivity
Reacts with
Human
Immunogen
Synthetic peptide based on the propeptide region of human MMP13.
Positive control
Cell media from human chondrosarcoma (treated with IL1 beta or TNF alpha).
Properties
Form
Liquid
Storage instructions
Store at +4°C short term (1-2 weeks). Aliquot and store at -20°C long term. Avoid repeated freeze / thaw cycles.
Storage buffer
Preservative: 0.05% Sodium Azide
Constituents: 50% Glycerol
Concentration
Concentration information loading...
Purity
Immunogen affinity purified
Primary antibody notes
The low endogenous MMP13 protein levels may require concentration of samples by ultrafiltration or ammonium sulfate precipitation prior to Western blotting.
Clonality
Polyclonal
Isotype
IgG
Research areas
Cancer >> Tumor biomarkers >> Enzymes >> MMPs
Cell Biology >> Proteolysis / Ubiquitin >> Proteolytic enzymes >> Metalloprotease >> MMPs
Cancer >> Invasion/microenvironment >> ECM >> Extracellular matrix >> MMPs
Cancer >> Invasion/microenvironment >> Angiogenesis >> ECM enzymes >> MMPs
Signal Transduction >> Cytoskeleton / ECM >> Extracellular Matrix >> ECM Enzymes >> MMP
Cardiovascular >> Angiogenesis >> Adhesion / ECM >> Matrix Metalloproteinases >> MMP
-
Western blot - MMP13 antibody (ab39023)
(enlarge)
Applications
Show applications key
Our Abpromise guarantee covers the use of ab39023 in the following tested applications.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
- 1 Image
WB
Application notes
WB: Recommended starting dilution of 1/3000 (when using colorimetric substrates such as BCIP/NBT) and 1/6000 (for chemiluminescent substrates). Higher concentrations of antibody may be needed for non human samples. The antibody recognizes the latent proenzyme, at 60 kDa, as well as the active form at 48 kDa, and intermediate activation forms. When used against the reduced protein, the antibody identifies a band at 60 kDa (predicted molecular weight: 54 kDa). Dilution optimised using Chromogenic detection. Not yet tested in other applications. Optimal dilutions/concentrations should be determined by the end user.
Target
Function
Degrades collagen type I. Does not act on gelatin or casein. Could have a role in tumoral process.
Tissue specificity
Seems to be specific to breast carcinomas.
Involvement in disease
Defects in MMP13 are the cause of spondyloepimetaphyseal dysplasia Missouri type (SEMD-MO) [MIM:602111]. A bone disease characterized by moderate to severe metaphyseal changes, mild epiphyseal involvement, rhizomelic shortening of the lower limbs with bowing of the femora and/or tibiae, coxa vara, genu varum and pear-shaped vertebrae in childhood. Epimetaphyseal changes improve with age.
Defects in MMP13 are the cause of metaphyseal anadysplasia type 1 (MANDP1) [MIM:602111]. Metaphyseal anadysplasia consists of an abnormal bone development characterized by severe skeletal changes that, in contrast with the progressive course of most other skeletal dysplasias, resolve spontaneously with age. Clinical characteristics are evident from the first months of life and include slight shortness of stature and a mild varus deformity of the legs. Patients attain a normal stature in adolescence and show improvement or complete resolution of varus deformity of the legs and rhizomelic micromelia.
Sequence similarities
Belongs to the peptidase M10A family.
Contains 4 hemopexin-like domains.
Domain
The conserved cysteine present in the cysteine-switch motif binds the catalytic zinc ion, thus inhibiting the enzyme. The dissociation of the cysteine from the zinc ion upon the activation-peptide release activates the enzyme.
Cellular localization
Secreted > extracellular space > extracellular matrix.
Target information above from: UniProt accessionP45452
The UniProt Consortium
The Universal Protein Resource (UniProt) in 2010
Nucleic Acids Res. 38:D142-D148 (2010).
Alternative names
- CLG 3 antibody
- CLG3 antibody
- Collagenase 3 antibody
see all
Database links
- Entrez Gene: 4322 Human
- Omim: 600108 Human
- SwissProt: P45452 Human
- SwissProt: Q6NWN6 Human
- Unigene: 2936 Human
Anti-MMP13 antibody - Propeptide domain images:
Western blot - MMP13 antibody (ab39023)
All lanes : Anti-MMP13 antibody - Propeptide domain (ab39023) at 1/3000 dilution
Lane 1 : Cell media from human chondrosarcoma (not treated)
Lane 2 : Cell media from human chondrosarcoma (treated with IL1 beta)
Lane 3 : Cell media from human chondrosarcoma (treated with TNF alpha)
Predicted band size : 54 kDa
Observed band size : 56 kDa (why is the actual band size different from the predicted?)
Protocols
References for Anti-MMP13 antibody - Propeptide domain (ab39023)
ab39023 has not yet been referenced specifically in any publications.
Publishing research using ab39023? Please let us know so that we can cite the reference in this datasheet
Please note: All products are "FOR RESEARCH USE ONLY AND ARE NOT INTENDED FOR DIAGNOSTIC OR THERAPEUTIC USE"